Published in Cancer J on January 22, 2013
Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT00861614
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer | NCT01057810
Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer (NeoACT) | NCT00715104
Targeting the adaptive molecular landscape of castration-resistant prostate cancer. EMBO Mol Med (2015) 0.93
Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90
Prediction of treatment efficacy for prostate cancer using a mathematical model. Sci Rep (2016) 0.78
mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer. Hum Vaccin Immunother (2014) 0.78
Consumption of Soy Isoflavone Enriched Bread in Men with Prostate Cancer Is Associated with Reduced Proinflammatory Cytokines and Immunosuppressive Cells. Cancer Prev Res (Phila) (2015) 0.77
The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions. Asian J Androl (2014) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol (2008) 18.54
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13
Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1995) 16.19
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity (1999) 12.36
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science (2001) 8.31
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med (1995) 8.31
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer (2009) 4.12
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother (2009) 3.70
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res (2005) 3.57
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol (2000) 3.48
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37
Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
Purification of a human prostate specific antigen. Invest Urol (1979) 3.11
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res (2004) 2.91
Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol (2008) 2.79
A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71
Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2004) 2.65
Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res (2004) 2.54
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol (2003) 2.51
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate (2002) 2.44
Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell (2005) 2.37
New therapies for castration-resistant prostate cancer. N Engl J Med (2010) 2.37
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res (2000) 2.28
Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer (1998) 2.15
Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol (2009) 2.04
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol (2010) 2.00
Molecular characteristics of immunogenic cancer cell death. Cell Death Differ (2007) 1.92
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci (2007) 1.89
Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist (2008) 1.85
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res (2000) 1.81
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Sipuleucel-T (Provenge®) for castration-resistant prostate cancer. BJU Int (2011) 1.61
Multiple costimulatory modalities enhance CTL avidity. J Immunol (2005) 1.58
Prospective analysis of laser photophacofragmentation. J Cataract Refract Surg (1990) 1.40
Effects of castration on thymocyte development in two different models of thymic involution. J Immunol (2005) 1.38
A viral vaccine encoding prostate-specific antigen induces antigen spreading to a common set of self-proteins in prostate cancer patients. Clin Cancer Res (2010) 1.30
Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res (2011) 1.29
Sipuleucel-T: a vaccine for metastatic, asymptomatic, androgen-independent prostate cancer. Ann Pharmacother (2007) 1.24
Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother (2008) 1.18
Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol Immunother (2010) 1.17
Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist (2008) 1.14
Poxvirus vaccines for cancer and HIV therapy. Expert Opin Biol Ther (2004) 1.12
DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother (2010) 1.12
Clinical evaluation of TRICOM vector therapeutic cancer vaccines. Semin Oncol (2012) 1.09
Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol (2004) 1.07
Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. Expert Opin Biol Ther (2010) 0.99
Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations. Cancer Immunol Immunother (2009) 0.98
Technology evaluation: APC-8015, Dendreon. Curr Opin Mol Ther (2002) 0.96
Kinetics of tumor-specific T-cell response development after active immunization in patients with HER-2/neu overexpressing cancers. Clin Immunol (2007) 0.93
Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother (2003) 0.90
Poxviral vectors for cancer immunotherapy. Expert Opin Biol Ther (2012) 0.88
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 0.87
Age-related changes in tissue levels of prostatic acid phosphatase and prostate specific antigen. J Urol (1986) 0.87
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 0.83
Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 0.83
Releasing the brakes on antitumor immune response. Science (1996) 0.81
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol (2003) 6.93
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A (2006) 6.90
Androgen deprivation therapy for prostate cancer. JAMA (2005) 6.07
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 5.12
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol (2007) 4.56
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 4.24
Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2002) 3.85
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA (2008) 3.55
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. Lancet Oncol (2011) 3.48
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A (2003) 3.34
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol (2004) 3.16
Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis. Ann Intern Med (2013) 2.96
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.51
Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res (2010) 2.45
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett (2007) 2.40
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Cancer vaccines: moving beyond current paradigms. Clin Cancer Res (2007) 2.40
Racial differences in screening for prostate cancer in the elderly. Arch Intern Med (2004) 2.34
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol (2003) 2.32
Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol (2008) 2.31
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol (2006) 2.29
A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24
A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. Lancet Oncol (2012) 2.24
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res (2006) 2.20
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease. Cancer (2013) 2.10
Chemotherapy for teratoma with malignant transformation. J Clin Oncol (2003) 2.06
Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol (2004) 2.02
Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res (2003) 1.99
Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res (2005) 1.98
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol (2008) 1.95
A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) (2010) 1.92
Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol (2009) 1.91
Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci (2007) 1.89
A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res (2008) 1.87
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.84
Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol (2007) 1.84
Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother (2012) 1.82
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res (2011) 1.82
Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin Cancer Res (2008) 1.81
p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A (2005) 1.80
Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiol Biomarkers Prev (2005) 1.80
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2011) 1.77
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol (2011) 1.75
Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 1.72
Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs (2009) 1.71
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2005) 1.68
Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer. Cancer (2008) 1.65
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Risk of prostate cancer recurrence in men treated with radiation alone or in conjunction with combined or less than combined androgen suppression therapy. J Clin Oncol (2008) 1.62
The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res (2005) 1.61
Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res (2008) 1.60
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer. J Urol (2005) 1.59
The likelihood of death from prostate cancer in men with favorable or unfavorable intermediate-risk disease. Cancer (2014) 1.58
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Safety and immunologic response of a viral vaccine to prostate-specific antigen in combination with radiation therapy when metronomic-dose interleukin 2 is used as an adjuvant. Clin Cancer Res (2008) 1.56
Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate (2012) 1.54
Time course and predictors of symptoms after primary prostate cancer therapy. J Clin Oncol (2003) 1.51
Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. J Clin Oncol (2011) 1.51
Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int (2013) 1.47
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. Urology (2013) 1.44
Risk of all-cause and prostate cancer-specific mortality after brachytherapy in men with small prostate size. Int J Radiat Oncol Biol Phys (2010) 1.44
Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J Clin Oncol (2008) 1.43
A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int (2008) 1.41
Germline CAG repeat length of the androgen receptor and time to progression in patients with prostate cancer treated with androgen deprivation therapy. BJU Int (2011) 1.41
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol (2011) 1.39
Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) (2008) 1.38
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. BJU Int (2009) 1.37
Costimulatory molecules as adjuvants for immunotherapy. Front Biosci (2006) 1.37
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
Predicting outcomes in prostate cancer: how many more nomograms do we need? J Clin Oncol (2007) 1.36
Development of an integrated prostate cancer research information system. Clin Genitourin Cancer (2006) 1.36
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A (2012) 1.34